- Home
- TPVG vs PVLA Comparison
TPVG vs PVLA Comparison
Compare TPVG & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- PVLA
- Stock Information
- Founded
- TPVG 2013
- PVLA 2015
- Country
- TPVG United States
- PVLA United States
- Employees
- TPVG N/A
- PVLA N/A
- Industry
- TPVG Other Consumer Services
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- PVLA Health Care
- Exchange
- TPVG Nasdaq
- PVLA Nasdaq
- Market Cap
- TPVG 253.9M
- PVLA 253.2M
- IPO Year
- TPVG N/A
- PVLA N/A
- Fundamental
- Price
- TPVG $6.72
- PVLA $22.05
- Analyst Decision
- TPVG Hold
- PVLA Strong Buy
- Analyst Count
- TPVG 6
- PVLA 7
- Target Price
- TPVG $6.55
- PVLA $46.29
- AVG Volume (30 Days)
- TPVG 269.0K
- PVLA 78.6K
- Earning Date
- TPVG 05-07-2025
- PVLA 05-15-2025
- Dividend Yield
- TPVG 17.91%
- PVLA N/A
- EPS Growth
- TPVG N/A
- PVLA N/A
- EPS
- TPVG 0.93
- PVLA N/A
- Revenue
- TPVG $101,260,000.00
- PVLA N/A
- Revenue This Year
- TPVG N/A
- PVLA N/A
- Revenue Next Year
- TPVG $5.37
- PVLA N/A
- P/E Ratio
- TPVG $7.24
- PVLA N/A
- Revenue Growth
- TPVG N/A
- PVLA N/A
- 52 Week Low
- TPVG $5.53
- PVLA $6.20
- 52 Week High
- TPVG $9.70
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- TPVG 59.79
- PVLA N/A
- Support Level
- TPVG $5.87
- PVLA N/A
- Resistance Level
- TPVG $6.69
- PVLA N/A
- Average True Range (ATR)
- TPVG 0.21
- PVLA 0.00
- MACD
- TPVG 0.11
- PVLA 0.00
- Stochastic Oscillator
- TPVG 98.26
- PVLA 0.00
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.